148 related articles for article (PubMed ID: 21338989)
1. Olmesartan severely weakened the development of NASH in an animal model of hypercholesterolemia.
Sturzeneker MC; Ioshii SO; Villela Baroncini LA; Précoma DB
Atherosclerosis; 2011 May; 216(1):97-102. PubMed ID: 21338989
[TBL] [Abstract][Full Text] [Related]
2. Effect of olmesartan on leukocyte recruitment in choroid-sclera complex in hypercholesterolemia model.
Torres RJ; de Noronha L; Casella AM; Grobe SF; Martins Ide C; Torres Rdo R; Luchini A; Sturzeneker MC; Torres CL; Precoma DB
J Ocul Pharmacol Ther; 2013 Oct; 29(8):709-14. PubMed ID: 23683100
[TBL] [Abstract][Full Text] [Related]
3. Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis.
Kitamura K; Tada S; Nakamoto N; Toda K; Horikawa H; Kurita S; Tsunematsu S; Kumagai N; Ishii H; Saito H; Hibi T
J Gastroenterol Hepatol; 2007 Nov; 22(11):2022-33. PubMed ID: 17914985
[TBL] [Abstract][Full Text] [Related]
4. Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition.
Yamamoto E; Dong YF; Kataoka K; Yamashita T; Tokutomi Y; Matsuba S; Ichijo H; Ogawa H; Kim-Mitsuyama S
Hypertension; 2008 Sep; 52(3):573-80. PubMed ID: 18678790
[TBL] [Abstract][Full Text] [Related]
5. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects.
Kurita S; Takamura T; Ota T; Matsuzawa-Nagata N; Kita Y; Uno M; Nabemoto S; Ishikura K; Misu H; Ando H; Zen Y; Nakanuma Y; Kaneko S
Eur J Pharmacol; 2008 Jul; 588(2-3):316-24. PubMed ID: 18501344
[TBL] [Abstract][Full Text] [Related]
6. Preventive role of genistein in an experimental non-alcoholic steatohepatitis model.
Yalniz M; Bahcecioglu IH; Kuzu N; Poyrazoglu OK; Bulmus O; Celebi S; Ustundag B; Ozercan IH; Sahin K
J Gastroenterol Hepatol; 2007 Nov; 22(11):2009-14. PubMed ID: 17914984
[TBL] [Abstract][Full Text] [Related]
7. [Effects of angiotensin II type 1 receptor blocker on triglyceride metabolism in the liver: experiment with Zucker fatty rats].
Ran JM; Lao GC; Xu G; Xie B; Zhang Y; Liu W; Feng Q; Guo J
Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(22):1557-61. PubMed ID: 18956640
[TBL] [Abstract][Full Text] [Related]
8. [Clinical and histological features of non-alcoholic fatty liver disease].
Shi JP; Xun YH; Hu CB; Zhang L; Liu H; Lou GQ; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638
[TBL] [Abstract][Full Text] [Related]
9. Effect of candesartan on the expression of sclera-choroidal intercellular adhesion molecule-1 in hypercholesterolemic models.
Torres RJ; Luchini A; Torres Rdo R; Oliveira LR; Torres CL; Torres RA; Olandoski M; Nagashima S; Noronha Ld; Precoma DB
Clinics (Sao Paulo); 2014 Feb; 69(2):145-9. PubMed ID: 24519206
[TBL] [Abstract][Full Text] [Related]
10. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.
Bedossa P; Poitou C; Veyrie N; Bouillot JL; Basdevant A; Paradis V; Tordjman J; Clement K
Hepatology; 2012 Nov; 56(5):1751-9. PubMed ID: 22707395
[TBL] [Abstract][Full Text] [Related]
11. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue.
Kudo H; Yata Y; Takahara T; Kawai K; Nakayama Y; Kanayama M; Oya T; Morita S; Sasahara M; Mann DA; Sugiyama T
Liver Int; 2009 Aug; 29(7):988-96. PubMed ID: 19386026
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
Verma S; Jensen D; Hart J; Mohanty SR
Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
[TBL] [Abstract][Full Text] [Related]
13. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.
Ong JP; Elariny H; Collantes R; Younoszai A; Chandhoke V; Reines HD; Goodman Z; Younossi ZM
Obes Surg; 2005 Mar; 15(3):310-5. PubMed ID: 15826462
[TBL] [Abstract][Full Text] [Related]
14. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.
Hong XZ; Li LD; Wu LM
Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732
[TBL] [Abstract][Full Text] [Related]
15. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement.
Dixon JB; Bhathal PS; O'Brien PE
Obes Surg; 2006 Oct; 16(10):1278-86. PubMed ID: 17059735
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits.
Arishiro K; Hoshiga M; Negoro N; Jin D; Takai S; Miyazaki M; Ishihara T; Hanafusa T
J Am Coll Cardiol; 2007 Apr; 49(13):1482-9. PubMed ID: 17397679
[TBL] [Abstract][Full Text] [Related]
17. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
Larter CZ; Yeh MM; Van Rooyen DM; Teoh NC; Brooling J; Hou JY; Williams J; Clyne M; Nolan CJ; Farrell GC
J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606
[TBL] [Abstract][Full Text] [Related]
18. Treatment of non-alcoholic steatohepatitis with Phyllanthus urinaria: a randomized trial.
Wong VW; Wong GL; Chan AW; Chu WC; Choi PC; Chim AM; Yiu KK; Yu J; Chan FK; Chan HL
J Gastroenterol Hepatol; 2013 Jan; 28(1):57-62. PubMed ID: 23034128
[TBL] [Abstract][Full Text] [Related]
19. Hyperlipidemic chicken as a model of non-alcoholic steatohepatitis.
Ayala I; Castillo AM; Adánez G; Fernández-Rufete A; Pérez BG; Castells MT
Exp Biol Med (Maywood); 2009 Jan; 234(1):10-6. PubMed ID: 18997102
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis.
Hirose A; Ono M; Saibara T; Nozaki Y; Masuda K; Yoshioka A; Takahashi M; Akisawa N; Iwasaki S; Oben JA; Onishi S
Hepatology; 2007 Jun; 45(6):1375-81. PubMed ID: 17518368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
